Based on our translational data, we recently observed encouraging response to a new type of immunotherapy called immune checkpoint inhibitors. Recurrent glioblastoma from CMMRD patients with hypermutation responded to the immune checkpoint inhibitor Nivolumab (Bouffet et al. JCO 2016).
In order to test new treatments for CMMRD, the International CMMRD Consortium is supporting two new international clinical trials which will test responses to immune checkpoint inhibition in recurrent CMMRD cancers. Biological correlative studies will be performed to determine the reasons for response or lack of for these therapies.
For more information on our clinical trials, and to see if you are eligible, please contact us at firstname.lastname@example.org or read more about the trials below.